osteoarthritis or Osteonecrosis of femoral head
Conditions
Interventions
Group A:Tranexamic acid (intravenous) + Carbazochrome sodium sulfonate(infiltration around joint capsule)
Group B:Tranexamic acid (intravenous)
Sponsors
Department of Orthopedics, West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. patients with osteoarthritis or osteonecrosis of the femoral head (Ficat III?IV) and have to undergo THA; 2. BMI 20-35 kg/m2; 3. American Society of Anesthesiologists grade I to III.
Exclusion criteria
Exclusion criteria: 1. The patients with anaphylactic acid, sodium carboxylic acid, anaesthesia drug allergy; 2. have a rigid hip joint, severe femoral deformity; 3. The posterior wall of the acetabulum was removed, and there was a history of surgery in the posterior hip; 4. The osteoarthritis (Crowe type 3 or 4) of DDH; 5. The history of thromboembolic disease (DVT), pulmonary embolism (PE), coagulopathy, recent arterial thromboembolic events (such as myocardial infarction or stroke), hypercoagulability, hemophilia; 6. Severe cardiovascular and respiratory diseases; Kidney and liver failure, kidney transplantation history; 7. Persons who refuse to participate in or refuse to accept blood products.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| total blood loss;haematocrit and haemoglobin (HB);reduction in haemoglobin concentration;transfusion rates; | — |
Secondary
| Measure | Time frame |
|---|---|
| intra-operative blood loss;Length of postoperative hospital stay;conglomeration parameter; | — |
Countries
China
Contacts
Public ContactKang Pengde
Department of Orthopedics, West China Hospital, Sichuan University
Outcome results
None listed